Home
Search
Study Topics
Glossary
|
Study 11 of 4246 for search of: | United States, Washington |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsors and Collaborators: |
Children's Oncology Group National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00016302 |
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: This phase II trial is studying several different combination chemotherapy regimens to see how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia.
Condition | Intervention | Phase |
---|---|---|
Leukemia |
Drug: asparaginase Drug: cyclophosphamide Drug: cytarabine Drug: daunorubicin hydrochloride Drug: dexamethasone Drug: doxorubicin hydrochloride Drug: leucovorin calcium Drug: mercaptopurine Drug: methotrexate Drug: nelarabine Drug: pegaspargase Drug: prednisone Drug: thioguanine Drug: vincristine sulfate Procedure: radiation therapy |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | The Use Of Modified BFM +/- Compound 506U78 (NSC# 686673) In an Intensive Chemotherapy Regimen For The Treatment Of T-Cell Leukemia |
Study Start Date: | April 2001 |
Primary Completion Date: | October 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 1 Year to 21 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Newly diagnosed T-cell acute lymphoblastic leukemia with greater than 25% bone marrow blasts (M3)
High-risk disease, defined as meeting at least 1 of the following criteria:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Study Chair: | Kimberly Dunsmore, MD | Children's Medical Center |
Study ID Numbers: | CDR0000068620, COG-AALL00P2 |
Study First Received: | May 6, 2001 |
Last Updated: | August 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00016302 |
Health Authority: | United States: Federal Government |
untreated childhood acute lymphoblastic leukemia T-cell childhood acute lymphoblastic leukemia |
Dexamethasone Asparaginase Prednisone Daunorubicin Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma Immunoproliferative Disorders Thioguanine Vincristine Leucovorin 6-Mercaptopurine Cyclophosphamide |
Doxorubicin Folic Acid Calcium, Dietary Pegaspargase Leukemia Lymphatic Diseases Leukemia, T-Cell Methotrexate Lymphoproliferative Disorders Lymphoma Cytarabine Dexamethasone acetate |
Anti-Inflammatory Agents Antimetabolites Anti-Infective Agents Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Reproductive Control Agents Antibiotics, Antineoplastic Hormones Vitamins Therapeutic Uses |
Abortifacient Agents Micronutrients Dermatologic Agents Alkylating Agents Nucleic Acid Synthesis Inhibitors Vitamin B Complex Neoplasms by Histologic Type Antineoplastic Agents, Hormonal Immune System Diseases Growth Substances Mitosis Modulators Gastrointestinal Agents Enzyme Inhibitors Antimitotic Agents Folic Acid Antagonists |